Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Total Non-current Liabilities
All obligations due after more than one year.
Pelthos Therapeutics Inc.AMEX: PTHS
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities remains negative
Q1 FY2026 total non-current liabilities was $85.27M, compared with $0 a year earlier.
Context
- Total non-current liabilities amounted to 58.7% of total assets at the end of Q1 FY2026, up 58.7 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 65.52M USD
- Year-over-year change
- —
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 65.52M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Total Non-current Liabilities vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 total non-current liabilities of $85.27M is the 2nd highest of the 4 companies compared; the peer median is $1.04M.
- Total non-current liabilities amounts to 58.7% of total assets for PTHS, versus a peer median of 4.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $383.03M | +128003.3% | +350.3% | 16.5% | |
| Mar 2026 | $85.27M | — | — | 58.7% | |
| Mar 2026 | $1.04M | +12.1% | +64.0% | 3.4% | |
| Mar 2026 | $461.77K | — | — | 4.2% | |
| Peer median (excluding PTHS) | $1.04M | +64007.7% | +207.2% | 4.2% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.